DTE
63
4
SO
70
4
EXPE
66
5
LB
64
9
PLD
48
5
DVA
71
5
AXP
59
6
NEM
50
2
TMO
47
4
HP
36
3
WMB
60
4
KMI
77
4
CCL
53
6
URI
42
-4
ACN
29
-4
SCHW
67
6
AKAM
35
3
KSS
23
2
VRSK
66
-2
AME
54
6
DTE
63
4
SO
70
4
EXPE
66
5
LB
64
9
PLD
48
5
DVA
71
5
AXP
59
6
NEM
50
2
TMO
47
4
HP
36
3
WMB
60
4
KMI
77
4
CCL
53
6
URI
42
-4
ACN
29
-4
SCHW
67
6
AKAM
35
3
KSS
23
2
VRSK
66
-2
AME
54
6
Financhill
Back

Stereotaxis 10K Form

Sell
22

STXS
Stereotaxis

Last Price:
$1.95
Seasonality Move:
-6.29%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STXS News And Ratings

See the #1 stock for the next 7 days that we like better than STXS

STXS Financial Statistics

Sales & Book Value

Annual Sales: $26.9M
Cash Flow: $-4.3M
Price / Cash Flow: 0
Annual Sales: $0.07
Price / Book: 25.68

Profitability

EPS (TTM): -0.30000
Net Income (TTM): $-24M
Gross Margin: $14.6M
Return on Equity: -139.2%
Return on Assets: -55.91%

Stereotaxis Earnings Forecast

Key Stereotaxis Financial Ratios

  • The Gross Profit Margin over the past 25 years for STXS is 54.22%.
  • The Selling, General & Administrative Expenses for STXS have been equal to 109.86% of Gross Profit Margin.
  • The Research & Development expenses have been 36.26% of Revenue.
  • The Interest Expense is 17.13% of Operating Income.
  • The Net Earning history of STXS is -89.33% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 13 years.

Stereotaxis Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: STXS
CUSIP: 85916J
Website: stereotaxis.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.22
Quick Ratio: 0.74

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STXS Technical Analysis vs Fundamental Analysis

Sell
22
Stereotaxis (STXS) is a Sell

Is Stereotaxis a Buy or a Sell?

  • Stereotaxis stock is rated a Sell
    The current Stereotaxis [STXS] share price is $1.83. The Score for STXS is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.